These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20022992)

  • 1. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
    Webb SM; Mo D; Lamberts SW; Melmed S; Cavagnini F; Pecori Giraldi F; Strasburger CJ; Zimmermann AG; Woodmansee WW;
    J Clin Endocrinol Metab; 2010 Feb; 95(2):630-8. PubMed ID: 20022992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood.
    Ragnarsson O; Höybye C; Jönsson PJ; Feldt-Rasmussen U; Johannsson G; Biller BM; Koltowska-Häggström M
    Eur J Endocrinol; 2012 Apr; 166(4):593-600. PubMed ID: 22258111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
    Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Bunderen CC; van Varsseveld NC; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Eur J Endocrinol; 2014 Dec; 171(6):717-26. PubMed ID: 25227133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.
    Höybye C; Ragnarsson O; Jönsson PJ; Koltowska-Häggström M; Trainer P; Feldt-Rasmussen U; Biller BM
    Eur J Endocrinol; 2010 Apr; 162(4):677-84. PubMed ID: 20089548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas.
    Auer MK; Stalla GK; Stieg MR
    Pituitary; 2016 Oct; 19(5):461-71. PubMed ID: 27194386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
    Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
    Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density.
    Colson A; Brooke AM; Walker D; Besser GM; Chew SL; Grossman AB; Jenkins PJ; Drake WM; Monson JP
    Horm Res; 2006; 66(6):257-67. PubMed ID: 16914933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
    Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease.
    Johannsson G; Sunnerhagen KS; Svensson J
    Clin Endocrinol (Oxf); 2004 May; 60(5):550-9. PubMed ID: 15104557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypopituitarism in Cushing's disease.
    Cavagnini F; Scacchi M; Pecori Giraldi F
    J Endocrinol Invest; 2008 Sep; 31(9 Suppl):44-7. PubMed ID: 19020385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease.
    Tiemensma J; Biermasz NR; Middelkoop HA; van der Mast RC; Romijn JA; Pereira AM
    J Clin Endocrinol Metab; 2010 Oct; 95(10):E129-41. PubMed ID: 20660031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas.
    Yener S; Ertilav S; Secil M; Akinci B; Demir T; Kebapcilar L; Yesil S
    Med Princ Pract; 2012; 21(5):429-34. PubMed ID: 22398948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
    van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.
    Verweij T; Slagboom TNA; van Varsseveld NC; van der Lely AJ; Drent ML; van Bunderen CC
    Eur J Endocrinol; 2021 Oct; 185(6):793-801. PubMed ID: 34605771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased prevalence of anxiety-associated personality traits in patients with Cushing's disease: a cross-sectional study.
    Dimopoulou C; Ising M; Pfister H; Schopohl J; Stalla GK; Sievers C
    Neuroendocrinology; 2013; 97(2):139-45. PubMed ID: 22572774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement.
    Attanasio AF; Mo D; Erfurth EM; Tan M; Ho KY; Kleinberg D; Zimmermann AG; Chanson P;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):74-81. PubMed ID: 19897679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.
    Giordano R; Picu A; Marinazzo E; D'Angelo V; Berardelli R; Karamouzis I; Forno D; Zinnà D; Maccario M; Ghigo E; Arvat E
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):354-60. PubMed ID: 21521323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.